New lupus treatments
Anifrolumab, belimumab and other targeted drugs in systemic lupus.
Key point
Biologics have been increasingly incorporated into the treatment algorithm at earlier stages of SLE and are first-line treatments for certain manifestations such as lupus nephritis.
From: Update to the Sociedad Española de Reumatología Guidelines on the Use of Biological Therapy in Systemic Lupus Erythematosus (Reumatol Clin (Engl Ed), 2026 Aug-Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 10, 10, 12, 15, 17.
New guidelines and consensus this year
- Update to the Sociedad Española de Reumatología Guidelines on the Use of Biological Therapy in Systemic Lupus ErythematosusReumatol Clin (Engl Ed)2026 Aug-Sep
- KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisAm J Kidney Dis2026 Aug
- EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 updateAnn Rheum Dis2026 Jan
All papers from the last 12 months
262 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Targeting IFN signaling as therapeutic option for lupus nephritisAutoimmunity2026 Dec 31PMID 42642989Review
- Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in ChinaLancet2026 Dec 20PMID 41240964
- Responsiveness of patient-reported outcomes by disease trajectory in systemic lupus erythematosusRheumatology (Oxford)2026 Oct 15PMID 42879728
- Obinutuzumab in Active Systemic Lupus Erythematosus. ReplyN Engl J Med2026 Oct 15PMID 42874118
- Obinutuzumab in Active Systemic Lupus ErythematosusN Engl J Med2026 Oct 15PMID 42874117
- Long-term comparative outcomes of rituximab and belimumab in lupus patientsRheumatology (Oxford)2026 Oct 14PMID 42873589
- Suboptimal attainment of SLE treat-to-target goals based on persistently high physician global assessment: an analysis of German SPOCS patientsLupus Sci Med2026 Oct 12PMID 42863888
- Sex-based differences in clinical phenotype and damage accrual among patients with systemic lupus erythematosus in Saudi Arabia: a multicenter cross-sectional studyClin Rheumatol2026 Oct 7PMID 42842163
- Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximabJ Eur Acad Dermatol Venereol2026 Oct 6PMID 42836361Review
- Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysisClin Rheumatol2026 Oct 5PMID 42832020
More rheumatology trends
All specialties →CAR-T for autoimmune disease
CAR-T cell therapy for lupus, systemic sclerosis and myositis.
Rheumatic immune-related adverse events
Arthritis, myositis and other rheumatic side effects of checkpoint inhibitors.
Ultrasound in rheumatology
Musculoskeletal and vascular ultrasound for diagnosis and monitoring.
Lung disease in systemic sclerosis
Interstitial lung disease in systemic sclerosis.
Giant cell arteritis and PMR
Giant cell arteritis, polymyalgia rheumatica and steroid-sparing treatment.
Key point: In PMR, interleukin-6 receptor blockers should be considered with glucocorticoids for relapsing disease and can be considered for new-onset high-risk patients.
Psoriatic arthritis
Psoriatic arthritis and its targeted treatments.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"systemic lupus erythematosus"[tiab] AND (anifrolumab[tiab] OR belimumab[tiab] OR obinutuzumab[tiab] OR deucravacitinib[tiab] OR litifilimab[tiab] OR dapirolizumab[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.